Researcher
Jurgen Joossens
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Tech Transfer Office (TTO) (Research group)
Responsible
From1 Nov 2016 → Today - Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2005 → 31 Oct 2016
Projects
1 - 10 of 21
- AI-driven optimalisation of the user experience (UX) of digital tools.From1 Sep 2023 → TodayFunding: IOF - technology concept exploration
- CremAN: Simulating Input/Output and CAN communication for testing remanufactured automotive parts.From1 May 2023 → TodayFunding: IOF - technology concept exploration
- Optimization of the cryopreservation procedure of cells for therapeutic and research applications using Design of Experiments.From1 Jan 2023 → 31 Dec 2023Funding: IOF - technology concept exploration
- IOF Alliance Valorisation Manager UAntwerpen - UZAFrom7 Nov 2022 → TodayFunding: IOF - mandates
- IOF Valorisation Life SciencesFrom7 Mar 2022 → TodayFunding: IOF - mandates
- Development of a cascading approach for zero-waste valorization of agricultural and food residues.From1 Dec 2021 → 30 Nov 2023Funding: IOF - technology concept exploration
- IOF Valorisation - Project DevelopmentFrom1 Jul 2021 → TodayFunding: IOF - mandates
- Towards integrated Practices of Schools, Reception Centres and Leisure Time Facilities for Refugee Children: an Action Research.From1 May 2021 → 30 Apr 2023Funding: IOF - technology concept exploration
- IOF Valorisation of social and human sciences.From1 Mar 2021 → TodayFunding: IOF - mandates
- IOF Valorisation Life SciencesFrom1 Jan 2021 → 16 Jul 2021Funding: IOF - mandates
Publications
31 - 40 of 50
- The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics(2015)
Authors: Jeroen van Soom, Giuliana Cuzzucoli Crucitti, Rafaela Gladysz, Pieter Van Der Veken, Roberto Di Santo, Ingmar Stuyver, Victoria Buck, Viktor Magdolen, Jurgen Joossens, Koen Augustyns
Pages: 1954 - 1958 - Synthesis and preclinical evaluation of an $^{18}F$ labeled PDE7 inhibitor for PET neuroimaging(2015)
Authors: David Thomae, Stijn Servaes, Naiara Vázquez, Leonie Wyffels, Stefanie Dedeurwaerdere, Pieter Van Der Veken, Jurgen Joossens, Koen Augustyns, Sigrid Stroobants, Steven Staelens
Pages: 975 - 981 - Repositioning the Substrate Activity Screening (SAS) approach as a fragment-based method for identification of weak binders(2014)
Authors: Rafaela Gladysz, Matthias Cleenewerck, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
Pages: 2238 - 2247 - Synthesis and in vivo preclinical evaluation of a $^{18}F$ labeled uPA inhibitor as a potential PET imaging agent(2014)
Authors: Johan Ides, David Thomae, Leonie Wyffels, Christel Vangestel, Jonas Messagie, Jurgen Joossens, Filip Lardon, Pieter Van Der Veken, Koen Augustyns, Sigrid Stroobants, et al.
Pages: 477 - 487 - Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold(2014)
Authors: Koen Jansen, Hans De Winter, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, Ingrid De Meester, Koen Augustyns, Pieter Van Der Veken
Pages: 1700 - 1707 - Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)(2014)
Authors: Koen Jansen, Leen Heirbaut, Robert Verkerk, Jonathan D. Cheng, Jurgen Joossens, Paul Cos, Ingrid De Meester, Koen Augustyns, Pieter Van Der Veken
Pages: 3053 - 3074 - From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds(2014)
Authors: Muthusamy Venkatraj, Jan Heeres, Jurgen Joossens, Bertrand Dirié, Sophie Lyssens, Johan Michiels, Paul Cos, Pieter Van Der Veken, Koen Augustyns
Pages: 5241 - 5248 - Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1(2014)
Authors: Carolien Grammen, Kevin Ariën, Muthusamy Venkatraj, Jurgen Joossens, Pieter Van Der Veken, Jan Heeres, Koen Augustyns, Guido Vanham, et al.
Pages: 113 - 121 - In vivo evaluation of $^{18}F$-labeled TCO for pre-targeted PET imaging in the brain(2014)
Authors: Leonie Wyffels, David Thomae, Ann-Marie Waldron, Jens Fissers, Stefanie Dedeurwaerdere, Pieter Van Der Veken, Jurgen Joossens, Sigrid Stroobants, Koen Augustyns, Steven Staelens
Pages: 513 - 523 - Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold(2013)
Authors: Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, Oksana Ryabtsova, Paul Cos, Ingrid De Meester, Koen Augustyns, Pieter Van Der Veken
Pages: 491 - 496
Patents
1 - 10 of 10
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- Triazines with suitable spacers for treatment and/or prevention of HIV infections (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)